July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

July 2019 Bonus Mid-Year Issue

Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.

Table of Contents

July 2019 Bonus Mid-Year Issue

Modern Medicine and Modern Stoicism

Monday, July 15th, 2019
One of the things I have found myself particularly struggling with as a fairly new attending is accepting that patients are free to make...

July 2019 Bonus Mid-Year Issue

Research espionage

The Spy Next Door?

Monday, July 15th, 2019
Academic institutions and government organizations strive to prevent research espionage while maintaining open scientific collaborations For decades, the U.S. has fostered international research collaborations with...

July 2019 Bonus Mid-Year Issue

Adding Pneumatic Compression to Heparin Therapy Does Not Reduce DVT in Critically Ill Patients

Monday, July 15th, 2019
According to results from the PREVENT trial, adjunctive pneumatic compression plus pharmacologic thromboprophylaxis did not lower the risk of new lower-limb deep vein thrombosis...

Mixed Opinions on Quizartinib From the FDA and Japanese Regulators

Monday, July 15th, 2019
After the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee decided against recommending approval of quizartinib for patients with relapsed/refractory FLT3-ITD acute...
WIB_icon

Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...

Monday, July 15th, 2019
If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

Monday, July 15th, 2019
According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...

Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL

Monday, July 15th, 2019
The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...

Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma

Monday, July 15th, 2019
In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...

FDA Approves First Anticoagulant for Pediatric Patients

Monday, July 15th, 2019
The FDA approved dalteparin sodium, administered as a subcutaneous injection, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients (≥1 month). Dalteparin...

Trump Administration Ends Fetal Tissue Research at NIH

Monday, July 15th, 2019
In June, the Department of Health and Human Services (HHS) announced a new policy curtailing government-funded research that uses fetal tissue donated after elective...
On location

Gilteritinib Outperforms Standard Chemotherapy in FLT3-Mutated AML, Regardless of Mutation Burden

Monday, July 15th, 2019
According to an analysis from the phase III ADMIRAL trial, treatment with gilteritinib was associated with higher response rates and longer survival than chemotherapy...
WIB_icon

Study Finds Urgent Need for Sickle Cell Disease Screening Among African Refugees in Italy

Monday, July 15th, 2019
Most refugees who arrive at the Mediterranean coast of Italy and other southern European countries are leaving areas where sickle cell disease (SCD) is...

FDA Recalls Three Hematology Analyzers

Monday, July 15th, 2019
The FDA issued a Class I recall of three hematology analyzers – Beckman Coulter DxH 800, DxH 600, and DxH 900 – after reports...

July 2019 Bonus Mid-Year Issue

On location

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

Monday, July 15th, 2019
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
On location

Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis

Monday, July 15th, 2019
In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm,...
On location

Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia

Monday, July 15th, 2019
Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to myelosuppression, but according to results from a study presented...
On location

Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas

Monday, July 15th, 2019
In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half of patients responded to treatment with REGN1979, an anti-CD20...
On location

Evaluating Rozanolixizumab in Primary Immune Thrombocytopenia

Monday, July 15th, 2019
Rozanolixizumab, at doses ranging from 4 to 15 mg/kg, induced platelet responses in patients with primary immune thrombocytopenia (ITP), according to an interim analysis...
On location

Polatuzumab Vedotin Combination Appears Effective in Relapsed/Refractory Follicular Lymphoma

Monday, July 15th, 2019
Treatment with the CD79b-directed antibody drug conjugate polatuzumab vedotin, when combined with obinutuzumab and lenalidomide, was associated with high rates of complete response (CR)...
On location

Dasatinib Plus Blinatumomab Increases Response and MRD Negativity in Ph-Positive Acute Lymphocytic Leukemia

Monday, July 15th, 2019
Combining the second-generation tyrosine kinase inhibitor (TKI) dasatinib with the bispecific monoclonal antibody blinatumomab induced high response rates in adult patients with Philadelphia chromosome...
On location

Gilteritinib Outperforms Standard Chemotherapy in FLT3-Mutated AML, Regardless of Mutation Burden

Monday, July 15th, 2019
According to an analysis from the phase III ADMIRAL trial, treatment with gilteritinib was associated with higher response rates and longer survival than chemotherapy...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

Monday, July 15th, 2019
According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...

SHARE